Administering Bispecifics to Patients with R/R MM

Ralph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.

Ralph V. Boccia, MD, FACP, explained the caregiver’s role in monitoring and reporting during bispecific antibody step-up dosing.

Ralph V. Boccia, MD, FACP, explained who needs REMS certification and which care team members need training to deliver bispecific antibodies.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed quadruplet induction, extended maintenance, and when a community clinician should call a myeloma center.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed the threshold he will act on in standard-risk disease, and the trial that would make the decision firmer.

In a retrospective analysis, teclistamab produced response rates numerically higher than in MajesTEC-1, with missed doses not compromising outcomes.

Data from the phase 3 OCEAN trial and others support the expanded approval for melflufen in patients with previously treated multiple myeloma.

In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.